Your browser doesn't support javascript.
loading
BerEP4-Negative Basal Cell Carcinoma: An Immunophenotype Not to Forget.
Murray, Douglas W; Thiel, Robert W; Phillips, Mariana A; Grider, Douglas J.
Afiliação
  • Murray DW; Virginia Tech Carilion School of Medicine, Roanoke, VA.
  • Thiel RW; Section of Dermatology, Department of Internal Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA.
  • Phillips MA; Virginia Tech Carilion School of Medicine, Roanoke, VA.
  • Grider DJ; Section of Dermatology, Department of Internal Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA.
Am J Dermatopathol ; 46(6): 386-388, 2024 Jun 01.
Article em En | MEDLINE | ID: mdl-38457681
ABSTRACT
ABSTRACT Basal cell carcinoma (BCC) is the most common cancer worldwide. Although not typically metastatic, BCC can be locally destructive. BerEP4 is an antibody against CD326, an epithelial cell adhesion molecule (EpCAM) that is expressed on epithelial progenitor cells and carcinomas. BerEP4 has been reported to have a 100% positive sensitivity in basal cell carcinomas, but a much lower sensitivity for a variety of other carcinomas, including clear cell renal cell carcinoma and metastatic renal cell carcinoma. A 74-year-old woman presented with a BerEP4-negative, but anti-renal cell antibody-positive BCC, and the stark clinical implications of misdiagnosis. This case stresses the importance of considering BerEP4-negative BCC, even when other abnormal features are present.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma Basocelular / Biomarcadores Tumorais Limite: Aged / Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma Basocelular / Biomarcadores Tumorais Limite: Aged / Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article